Cargando…
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status
BACKGROUND: Current clinical guidelines suggest that breast cancers with low hormone receptor expression (LowHR) in 1–10% of tumor cells should be regarded as hormone receptor positive. However, clinical data show that these patients have worse outcome compared to patients with hormone receptor expr...
Autores principales: | Jurmeister, Philipp, Weber, Karsten, Villegas, Sonia, Karn, Thomas, Untch, Michael, Thieme, Anne, Müller, Volkmar, Taube, Eliane, Fasching, Peter, Schmitt, Wolfgang D., Marmé, Frederik, Stickeler, Elmar, Sinn, Bruno V., Jank, Paul, Schem, Christian, Klauschen, Frederick, van Mackelenbergh, Marion, Denkert, Carsten, Loibl, Sibylle, Capper, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489064/ https://www.ncbi.nlm.nih.gov/pubmed/34602069 http://dx.doi.org/10.1186/s13148-021-01176-5 |
Ejemplares similares
-
Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
por: Witzel, Isabell, et al.
Publicado: (2019) -
Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial
por: Stevic, Ines, et al.
Publicado: (2018) -
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
por: Jank, Paul, et al.
Publicado: (2020) -
Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
por: Jank, Paul, et al.
Publicado: (2021) -
Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging
por: Gonçalves, Juliana Pereira Lopes, et al.
Publicado: (2023)